SAB Biotherapeutics, Inc.

SABS · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Assets
Cash & Equivalents$29,425$3,692$5,640$8,898
Short-Term Investments$81,456$2,021$7,210$11,863
Receivables$560$0$21$55
Inventory$0$0$0$0
Other Curr. Assets$1,836$3,595$3,425$2,977
Total Curr. Assets$113,277$9,308$16,297$23,792
Property Plant & Equip (Net)$19,439$20,404$21,374$19,921
Goodwill$0$0$0$0
Intangibles$0$0$0$0
Long-Term Investments$50,609$0$0$0
Tax Assets$0$0$0$0
Other NC Assets$124$417$450$482
Total NC Assets$70,172$20,821$21,823$20,403
Other Assets$0$0$0$0
Total Assets$183,448$30,129$38,120$44,195
Liabilities
Payables$2,955$2,622$2,520$1,695
Short-Term Debt$988$963$1,077$812
Tax Payable$0$0$0$0
Deferred Revenue$0$0$0$0
Other Curr. Liab.$6,850$7,092$6,056$5,473
Total Curr. Liab.$10,793$10,677$9,653$7,980
LT Debt$5,199$5,455$5,706$3,857
Deferred Rev, NC$0$0$0$0
Deferred Tax Liab, NC$0$0$0$0
Other NC Liab.$2,382$1,981$1,353$6,389
Total NC Liab.$7,581$7,436$7,059$10,246
Other Liabilities$0$0$0$0
Cap. Leases$0$6,419$6,644$3,857
Total Liabilities$18,374$18,113$16,713$18,226
Equity
Pref Stock$0$0$0$0
Common Stock$5$1$1$1
Retained Earnings-$94,034-$139,480-$129,366-$124,169
AOCI$71-$16-$112-$135
Other Equity$259,033$151,511$150,884$150,273
Total Equity$165,074$12,016$21,407$25,970
Supplemental Information
Minority Interest$0$0$0$0
Total Liab. & Tot. Equity$183,448$30,129$38,120$44,195
Net Debt-$23,237$2,726$1,143-$4,229